Related Experiment Video
Updated: Jun 13, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Management of multidrug-resistant tuberculosis: an update
Ignacio Monedero1, José A Caminero
1MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), 75006 Paris, France. imonedero@theunion.org
Therapeutic Advances in Respiratory Disease
|April 15, 2010
Summary
Multidrug-resistant tuberculosis (MDR-TB) management requires comprehensive programs, not just expensive drugs. Optimization of existing tools offers the best hope for curing MDR-TB patients, even with extensive resistance.
Area of Science:
- Public Health
- Infectious Diseases
- Microbiology
Background:
- Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health threat.
- Limited treatment options and the impact of HIV epidemics worsen patient prognosis.
- A lack of robust evidence and randomized controlled trials creates confusion in MDR-TB management.
Purpose of the Study:
- To critically review current best practices for diagnosing and treating MDR-TB.
- To highlight the need for comprehensive management programs over solely relying on new drugs.
- To emphasize the potential for cure using existing knowledge and effective logistics.
Main Methods:
- Critical review of existing literature and clinical guidelines.
- Analysis of current challenges and evidence gaps in MDR-TB treatment.
- Evaluation of management strategies focusing on comprehensive programs.
Main Results:
- MDR-TB control is threatened globally, with poor patient outcomes.
- Effective MDR-TB management necessitates structured programs and multi-participant involvement.
- Optimizing existing tools and applying current clinical knowledge are crucial for successful treatment outcomes.
Conclusions:
- Despite challenges, a majority of MDR-TB patients can be cured with optimized existing tools and effective logistics.
- Focus should be on comprehensive program development and application of current knowledge.
- New drugs and vaccines will take time to reach low and middle-income countries, making optimization of current strategies paramount.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.